Sort
4,870 grants matching “glp 1”
Borrelia burgdorferi tick phase genes and Lyme disease pathogenesis
$402,500Ira S. Schwartz · New York Medical College · R01 · FY2014 · AI
Borrelia burgdorferi tick phase genes and Lyme disease pathogenesis
$402,500Ira S. Schwartz · New York Medical College · R01 · FY2015 · AI
Borrelia burgdorferi tick phase genes and Lyme disease pathogenesis
$402,500Ira S. Schwartz · New York Medical College · R01 · FY2012 · AI
First-in-Human Clinical Translation of a Near-Infrared, Nerve-Specific Fluorophore to Facilitate Tissue-Specific Fluorescence-Guided Surgery
$402,162Eric R Henderson · Dartmouth-Hitchcock Clinic · R01 · FY2023 · NS
First-in-Human Clinical Translation of a Near-Infrared, Nerve-Specific Fluorophore to Facilitate Tissue-Specific Fluorescence-Guided Surgery
$402,132Eric R Henderson · Dartmouth-Hitchcock Clinic · R01 · FY2025 · NS
University of Maryland, Baltimore Biomarker Reference Laboratory
$401,644Sanford A Stass · University Of Maryland Baltimore · U24 · FY2012 · CA
Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium
$401,374Ankit Agarwal · Imbed Biosciences, Inc. · SB1 · FY2022 · AR
Preclinical Development of PEG-TNF
$401,250Phoenix Pharmacologics, Inc. · R44 · FY2004 · CA
Metabolic Function of Gpr17 in Gastrointestinal Tract
$401,224Hongxia Ren · Indiana University Indianapolis · R01 · FY2020 · DK
Metabolic Function of Gpr17 in Gastrointestinal Tract
$401,224Hongxia Ren · Indiana University Indianapolis · R01 · FY2022 · DK
Metabolic Function of Gpr17 in Gastrointestinal Tract
$401,224Hongxia Ren · Indiana University Indianapolis · R01 · FY2021 · DK
Metabolic Function of Gpr17 in Gastrointestinal Tract
$401,224Hongxia Ren · Indiana University Indianapolis · R01 · FY2023 · DK
Project 2: PK/PD requirements for mucolytic therapeutic agents in vitro and in vivo
$400,546Richard C Boucher · Univ Of North Carolina Chapel Hill · P01 · FY2019 · HL
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
$400,462Hamid Ghandehari · Theratarget · R42 · FY2016 · CA
Pharmacologic Enhancement of Viral Oncolysis
$400,162E. Antonio Chiocca · Massachusetts General Hospital · P01 · FY2010 · CA
Higher-Order Neural Control of Food Intake
$400,125Scott Edward Kanoski · University Of Southern California · R01 · FY2017 · DK
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
$400,000Zhirui Wang · Rock Immune Llc · R42 · FY2021 · CA
Advancing Next Generation CAR-T cells for Renal Cell Carcinoma
$400,000Premal Patel · Cellinfinity Bio, Inc. · R44 · FY2024 · CA
Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia
$400,000Natasha M. Nesbitt · Blood Cell Technologies, Llc · R44 · FY2025 · CA
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials
$400,000Xiang Ling · Canget Biotekpharma, Llc · R43 · FY2023 · CA
Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment
$399,999David A Ehrmann · University Of Chicago · U01 · FY2015 · DK
Efficacy of a novel small-molecule splicing modulator in chronic lymphocytic leukemia (CLL)
$399,999Thomas Roy Webb · Wildflower Biopharma Inc · R41 · FY2020 · CA
Assessment of a Digitally Controlled Aerosolized Nicotine Replacement Therapy
$399,989James M Davis · Predictably Human, Inc. · R42 · FY2024 · DA
Neupronâ¢: A Neuroprotective Agent for Treating Acute Spinal Cord Injury
$399,987Vinod D Labhasetwar · Axoneural Therapeutics, Inc. · R41 · FY2021 · NS
Modulation of cancer induced immune suppression via inhibition of SCD1
$399,986Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2022 · CA